News Archive 

IP Genesis reports successful launch of the Genboree Early Access Program


HOUSTON, TX (January 26th, 2009)

Upon acquisition of commercial licenses to Genboree and Pash software from Baylor College of Medicine, IP Genesis launched the Genboree Early Access Program in April 2008. The program aims to provide Genboree Hosting services to a small number of early clients who employ advanced genomic technologies such as massively parallel sequencing. Since the launch of the program, research projects conducted at three research institutions have been successfully completed.

The program has identified a growing need for semi-automated analysis of sequences generated by massively parallel sequencing. Favorable feedback received from current users indicates possible enrollment of additional program participants before the full launch of Genboree Hosting Services, which is anticipated to occur in the third quarter of 2009.

IP Genesis is a bioinformatics company formed for the purpose of enhancing discovery processes in life sciences. For more information about IP Genesis, Inc., visit their Web site at www.ipgenesis.com.

Contact: Mr. Matko Vladimir (713) 589 5463 mvladimir@ipgenesis.com



Baylor College of Medicine licenses CSA(TM) technology for comparative assembly of DNA sequences from IP Genesis, Inc.

 

HOUSTON, TX (July 8th, 2002)

Baylor College of Medicine acquired a non-exclusive license to IP Genesis, Inc.'s Comparative Sequence Assembly (CSA(TM) ) technology. CSA technology helps decipher the function of the human genome by determining sequences that are conserved across species and thus stand out in the midst of the vast majority of highly variable "junk" DNA. US Patent 6,001,562 covers the core CSA technology, including the fragment assembly of one nucleic acid by using sequence of a second, already assembled DNA sequence to guide the comparative assembly process. The Patent covers both the standard dideoxy method used in shotgun sequencing as well as hybridization-based methods employed by biochips.

"It is a great pleasure to welcome Baylor College of Medicine, a leader in molecular genetics, into our CSA program", said Dr. James Vlazny, Chief Licensing Officer for the CSA technology. "Comparative analyses through CSA have the potential to significantly speed up the deciphering of the human genome through comparative analyses against other mammalian genomes that are at different stages of sequence assembly, as well as speed up the assembly of the newly sequenced genomes."

Modern genome-scale "shotgun" DNA sequencing strategy involves two steps: first, determination of short randomly selected fragments of the DNA sequence; second, assembly of the fragments into contiguous sequence. The domino-like assembly is guided by overlaps of sequenced fragments. CSA technology reduces the amount of sequencing necessary for the assembly by utilizing the already assembled sequences of related organisms as a template to guide the assembly process. It is estimated that humans share about 90% of genes with other mammals, indicating a large potential of CSA to reduce the cost and increase the speed of sequencing. By comparing the genomes of different organisms, scientists can identify genome regions that play a pivotal role in the production of proteins, as well as the corresponding regulatory regions, which also tend to be conserved even across distantly related species.

IP Genesis is a bioinformatics company formed for the purpose of enhancing discovery processes in life sciences. For more information about IP Genesis, Inc., visit their Web site at www.ipgenesis.com.

Additional contacts:

Dr. James Vlazny (847) 724 0265 or send E-mail message to csa@ipgenesis.com at IP Genesis.

 

Argonne licenses DNA sequence analysis technology to IP Genesis

 

ARGONNE, Ill (January 28, 2002)

Comparative Sequence Assembly, a new technology for comparative DNA sequencing and analysis developed at the U.S. Department of Energy's Argonne National Laboratory, has been licensed exclusively to IP Genesis, Inc., a company based in Houston, Texas. IP Genesis expects to launch a CSA(TM) sublicensing program this year, with an aim to enable deciphering of genomic information through large-scale application of the technology.

"The newly available human genomic sequence has been often referred to as the 'Book of Life.' In order to understand the meaning of this 'Book,' however, we first need to understand the language in which it is written." explains Dr. Aleksandar Milosavljevic, former Argonne scientist who developed the sequencing technology. Milosavljevic, who founded IP Genesis, added, "An essential step in the learning of any new language is the reading of related texts. This is where Comparative Sequence Assembly fits in. The CSA technology enables the deciphering of the human genome through comparative analysis against the genomes of other primates, mouse, rat, and other organisms.

The patented technology includes a combined step of fragment assembly of one nucleic acid and sequence comparison against a second, already assembled, DNA sequence. The information gleaned through CSA technology enables discovery of basic molecular mechanisms of disease and the discovery of drug targets and novel therapies.

IP Genesis is a new bioinformatics and genomics company. For more information about IP Genesis, Inc., visit their Web site at www.ipgenesis.com.

With more than 200 different programs in basic and applied research, Argonne is one of the nation's largest federally funded scientific laboratories. The University of Chicago operates Argonne for the U.S. Department of Energy.